Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: J Invest Dermatol. 2020 Feb 20;140(8):1609–1618.e7. doi: 10.1016/j.jid.2020.01.027

TERT, BRAF, and NRAS mutational heterogeneity between paired primary and metastatic melanoma tumors

Gregory A Chang 1,6,9,*, Jennifer M Wiggins 1,6,*, Broderick C Corless 1,6,10,*, Mahrukh M Syeda 1,6, Jyothirmayee S Tadepalli 1,6, Shria Blake 8, Nathaniel Fleming 1,6, Farbod Darvishian 4,6, Anna Pavlick 1,2,6, Russell Berman 3,6, Richard Shapiro 3,6, Yongzhao Shao 5,6, George Karlin-Neumann 7, Cindy Spittle 8, Iman Osman 1,2,6, David Polsky 1,6
PMCID: PMC7387168  NIHMSID: NIHMS1568745  PMID: 32087194

Abstract

Mutational heterogeneity can contribute to therapeutic resistance in solid cancers. In melanoma, the frequency of inter- and intra-tumoral heterogeneity is controversial. We examined mutational heterogeneity within individual melanoma patients using multi-platform analysis of commonly mutated driver and non-passenger genes.

We analyzed paired primary and metastatic tumors from 60 patients, and multiple metastatic tumors from 39 patients whose primary tumors were unavailable (n=271 tumors). We used a combination of multiplex SNaPshot assays, Sanger Sequencing, Mutation-specific PCR, or droplet digital PCR to determine the presence of BRAFV600, NRASQ61, and TERT124C>T and TERT146C>T mutations.

Mutations were detected in BRAF (39%), NRAS (21%) and/or TERT (78%). Thirteen patients had TERTmutant discordant tumors; seven of these had a single tumor with both TERT124C>T and TERT146C>T mutations present at different allele frequencies. Two patients had both BRAF and NRAS mutations; one in different tumors and the other had a single tumor with both mutations. One patient with a BRAFmutant primary lacked mutant BRAF in least one of their metastases. Overall, we identified mutational heterogeneity in 18/99 (18%) patients.

These results suggest that some primary melanomas may be comprised of subclones with differing mutational profiles. Such heterogeneity may be relevant to treatment responses and survival outcomes.

INTRODUCTION

Inter and intra-tumor heterogeneity have been described in many solid cancers, and may be a source of therapeutic resistance (McGranahan and Swanton, 2017). Some subclones may be naturally resistant to a given treatment, while others arise in response to therapy. Thus, identification of tumor heterogeneity may be relevant when investigating treatment efficacy. Based on recent exome sequencing studies, melanoma and lung cancer are considered to have the least amount of mutational heterogeneity among non-synonymous (i.e. non-silent) gene mutations (McGranahan and Swanton, 2017). However, heterogeneous responses to BRAFMEKi therapy appear fairly common in melanoma, and are associated with reduced survivals (Carlino et al., 2013, Menzies et al., 2014a).

Although a meta-analysis of BRAF heterogeneity that only included studies with >10 melanoma patients concluded that BRAF mutational discrepancies between tumors occur at rates between 7% - 13% (Valachis and Ullenhag, 2017), some authors have questioned the underlying results. They cite either technical issues, or the existence of an undiagnosed second primary tumor to explain the reported mutational heterogeneity. (Menzies et al., 2014b, Riveiro-Falkenbach et al., 2017, Uguen et al., 2016).

In this study we explored melanoma mutational heterogeneity using multiple, longitudinally collected samples from patients prospectively enrolled in a melanoma biorepository program. We selected patients with at least two tumors available for analysis to assess the frequency of inter-tumor TERT, the most frequently mutated genes in melanoma. Their mutation rates are 52%, 28% and 64%, respectively (Akbani et al., 2015). This strategy allowed us to examine individual patients for inter-tumor heterogeneity between the primary and subsequent metastases, as well as between metastatic tumors. We undertook this investigation using multiple mutation-detection platforms to reduce the possibility of technical errors confounding the results.

RESULTS

Patient and sample characteristics

We studied 99 patients: 60 males and 39 females. Overall we analyzed 63 primary tumors from 60 patients and 208 metastases across all patients. Three patients had two primary tumors each. Thirty-nine patients had multiple metastatic tumors, but no primary tumor available. Patient demographics and clinical characteristics are summarized in Table 1. All patient tumors were assessed for the presence of BRAF, NRAS and TERT mutations using multiplex SNaPshot assays.

Table 1:

Summary of patient demographics and clinical characteristics.

Patients (n=99)

Age (mean, median) 56.8, 56
Gender
 Male (mean, median) 60 (58, 59)
 Female (mean, median) 39 (54.3, 54)
Primary tumors (n=63)
 Head/Neck 18
 Trunk 22
 Extremities 22
 Unclassified 1
Primary tumor thickness (mm)
 Range in situ − 30mm
in situ ≤ 0.9 10
 1 ≤ 1.9 17
 2 ≤ 3.9 19
 ≥ 4 17
Metastases (n=208)
 Lymphatic 131
 Hematogenous 77
Time to First Recurrence (Days) (n=90*)
 Range 51 – 4207
 Median 624
*

Patients lacking date of primary diagnosis were excluded

Multiplatform mutational analysis

We conducted quality control and validation of BRAF and NRAS mutations using more than one analytical platform on 248/271 (91.5%) samples based on DNA availability after SNaPshot analysis (Figure 1a). We used Mutation-specific PCR (MS-PCR), Sanger sequencing and/or droplet digital PCR (ddPCR) as orthogonal methods. SNaPshot and MS-PCR were 95% concordant (101/106 samples tested). All five discordant samples were resolved by a third analytical platform. SNaPshot was concordant with Sanger in 190/205 (93%) cases, and with ddPCR in 18/27 (67%) cases (Table S1).

Figure 1: Multiplatform analysis for quality control.

Figure 1:

Mutational profiles were determined using a combination of multiplex SNaPshot, Sanger sequencing, MS-PCR, or ddPCR. (a) Summary of BRAF and NRAS mutation detection methods and flow chart depicting the sequence of sample analysis. All 271 samples were tested by SNaPshot. One hundred and seven samples underwent MS-PCR validation. Samples with sufficient DNA were sent for Sanger Sequencing, including 138 analyzed by SNaPshot and 71 analyzed by both SNaPshot and MS-PCR. Thirty samples with sufficient DNA remaining were tested by ddPCR.

(b) Summary of TERT promoter mutation detection methods and results by method. Samples with sufficient DNA were tested by SNaPshot (268/271). Samples which presented with TERT promoter heterogeneity by SNaPshot (n=89) were tested using ddPCR. One sample was tested by ddPCR only.

To safeguard against false heterogeneity due to a potential lack of sensitivity of the SNaPshot platform, we tested 18 tumors labeled as wild-type based on SNaPshot analysis and/or MS-PCR or Sanger with ddPCR (a more sensitive method than SNaPshot). These tumors were from patients who had other tumors that tested positive for BRAF or NRAS mutations (and had sufficient remaining DNA). Unexpectedly we identified mutations in 10/18 (56%) of these tumors, thereby refining the number of patients with BRAF or NRAS inter-tumor heterogeneity. Of note, 10 samples classified as wild-type by SNaPshot, were not confirmed by another method. Only one of these 10 samples was from a patient with other BRAF or NRAS positive tumors. Recognizing the potential for SNaPshot to deliver a false negative mutation call and our inability to employ a second platform to confirm this result, we took a conservative approach and removed this patient from the heterogeneity group. The results from this patient (03–085) are described in Table S2a. The remaining nine tumors were from patients in which the all of their other tumors were wild-type.

With respect to TERT promoter mutations, the initial SNaPshot analysis yielded 31 patients with inter-tumor heterogeneity (Table S2). Given the high GC content and nucleotide repeats in this region, we re-tested all 89 tumors from these patients using TERT-mutation specific ddPCR assays (Corless et al., 2019) after uracil DNA glycosylase (UDG) treatment to reduce the likelihood of artifactual C-T changes (Do and Dobrovic, 2015). Using ddPCR we confirmed 45 mutated and nine wild-type tumors. We also identified previously undetected mutations in 27 tumors, as well as two SNaPshot false positives (i.e. ddPCR wild-type) likely due to C-T artifacts. Among five tumors that failed SNaPshot, ddPCR identified three mutants and one wild-type. One tumor failed ddPCR (Figure 1b). In total, UDG treatment followed by ddPCR reduced the number of patients with TERT inter-tumor heterogeneity from 31 to 13. Of note, 56 samples from 22 patients lacking TERT mutations in any of their tumors were labeled as wild-type by SNaPshot only. One other wild-type tumor was from a patient who had TERT promoter heterogeneity based on their other tumors, so the wild-type call on this tumor (P1) did not change the heterogeneity status of the patient (05–137) (Table S2).

After completion of the multiplatform analysis and quality control checks, our final analysis identified at least one BRAF, NRAS or TERT mutation in tumors from 87/99 (88%) patients. Thirty-nine (39%) had a detectable BRAFV600 mutation in at least one of their tumors and 21 (21%) patients had at least one NRASQ61 mutant tumor. TERT promoter mutations were identified in 77/99 (78%) patients with 35/99 (35%) having at least one −124 [C>T] mutant tumor, 35/99 (35%) having at least one −146 [C>T] mutant tumor, and 7/99 (7%) having at least one tumor with both mutations. The frequency of mutations by anatomic site are shown in Table S3. Overall, we observed mutational heterogeneity in 18 out of 99 patients (18%) (Table 2). Seven out of 99 (7%) displayed BRAF tumor heterogeneity, 3/99 (3%) had NRAS tumor heterogeneity, and the majority 13/99 (13%) displayed heterogeneity for TERT.

Table 2: Inter-tumor mutational heterogeneity per patient.

(a) Heterogeneity among patients with available primary (P) and metastatic tumors (M1, M2, etc.). (b) Heterogeneity among patients with no available primary (metastases only). Tumors are numbered based on order of chronological appearance. Tumors lacking a detectable mutation are denoted WT. Tumors with a detectable mutation are denoted MUT. Samples that failed to yield a clear result and are marked accordingly. Samples marked by * had low DNA concentrations. Sample marked as ** was wild-type by SNaPshot but failed ddPCR analysis (this patient was not included in the TERT heterogeneity group

a.
Patient ID Tumor Time from initial diagnosis (days) Anatomical Location Genes
BRAF NRAS TERT−124 [C>T] TERT−146 [c>T]

03–036 P 0 R Foot WT WT WT MUT
M1 673 R Inguinal MUT WT WT MUT
M2 1136 Brain MUT WT WT MUT

06–001 P 0 R Leg (lower front) MUT WT WT** WT**
M1 310 R Leg (lower front) WT MUT MUT WT
M2 3667 R Thigh WT MUT MUT WT
M3 4534 R Leg (upper front) WT MUT MUT WT

04–050 P1 0 L Ear WT WT MUT WT*
P2 2406 L Ear WT WT MUT MUT
M1 3855 L Ear MUT WT WT MUT
M2 4275 Front Neck WT WT WT MUT

08–090 P 0 Back WT WT WT WT
M1 0 R Axillary MUT WT WT MUT
M2 167 R Upper Back MUT WT WT MUT

03–092 P 0 R Upper Back WT MUT WT WT
M1 1954 Bone - Sternum WT MUT WT MUT

03–132 P 0 Back WT WT WT WT
M1 4315 L Supraclavivular WT WT MUT WT
M2 4402 N/A WT WT MUT WT

04–111 P 0 L Arm (upper ext) WT WT MUT WT
M2 785 L Arm WT WT MUT WT
M3 836 L Lower Back WT WT WT WT
M4 1015 L Arm WT WT MUT WT
M5 2152 L Arm WT WT MUT WT

04–168 P 0 L Arm MUT WT WT WT
M1 2625 L Axillary MUT WT MUT WT

05–137 P1 0 Chest WT WT WT WT
P2 5076 Scalp R Parietal WT WT MUT MUT
M1 5706 L Arm Deltoid WT WT MUT WT

06–002 P 0 Scalp MUT WT WT MUT
M1 8 R Post. Occipital MUT WT WT MUT
M2 8 R Post. Auricular MUT WT MUT MUT
M3 240 Brain MUT WT WT MUT

07–050 P 0 L Arm (upper front) MUT WT MUT MUT
M1 405 Brain MUT WT MUT WT

10–018 P 0 R Ear WT WT MUT MUT
M1 860 R Paratracheal WT WT WT WT
M2 860 Lung WT WT WT WT

b.
Patient ID Tumor Time from initial diagnosis (days) Anatomical Location Genes
BRAF NRAS TERT−124 [C>T] TERT−146 [c>T]

02–074 M1 0 Supraomohyoid WT WT MUT WT
M2 778 R Neck WT WT MUT MUT

03–103 M1 35 R Axillary WT MUT MUT MUT
M2 2439 Mediastinum WT MUT WT MUT

06–004 M1 0 R Upper Back MUT WT WT MUT
M2 693 Lung WT WT WT MUT
M3 1440 R Axillary WT WT WT MUT

06–040 M1 235 R Axillary WT WT MUT WT
M2 672 Brain MUT WT MUT WT
M3 836 Spine C1-C2 MUT WT MUT WT

06–075 M1 39 L Axillary MUT MUT WT WT
M2 398 L Flank WT MUT WT WT
M3 445 L Flank WT MUT WT WT

07–080 M1 265 R Calf WT MUT WT WT
M2 1318 Spleen WT WT MUT WT
M3 1318 Stomach WT WT MUT WT

Mutational heterogeneity between patients’ primary and metastatic tumors

Among patients who had available primary tumors, 12 out of 60 displayed mutational heterogeneity between their primary and metastatic tumors (Table 2). Eight of 12 patients (67%) had mutations detected in their metastatic tumors that were not detected in their primary tumors. Five of the eight patients had a newly detected TERT mutation in their metastases which was not found in their primary tumors. Interestingly, four patients had detectable BRAF (n=3) or NRAS (n=1) driver mutations in one of their metastases which was undetectable in their primary tumors (Table 3a).

Table 3: Patients with discordant mutations between primary and metastatic tumors.

Twelve patients had discordant mutations between their primary and metastatic tumors. Mutations which were gained (a), or were undetected (b) in at least one of their metastatic tumors are displayed by patient. Specific details for each patient are displayed in Table 2.

a.
Discordance between Primary and Metastatic Tumors
Patient # Mutations Gained in Metastasis
03–036 BRAF
03–092 TERT -146
03–132 TERT -124
04–050 BRAF
04–168 TERT -124
06–001 NRAS
06–002 TERT -124
08–090 TERT -146, BRAF
b.
Discordance between Primary and Metastatic Tumors
Patient # Mutations Absent in Metastasis
04–050 TERT -124
04–111 TERT -124
05–137 TERT -146
06–001 BRAF
07–050 TERT -146
10–018 TERT -124,-146

Unexpectedly, six of the 12 patients (50%) had mutations in their primary tumor that were undetectable in at least one of their metastases (Table 3b). Five of these six patients had TERT promoter mutations in the primary that were undetectable in one of their metastases. Similarly, one of these six patients (06–001) had a BRAF mutation in their primary that was undetectable in their metastatic tumors. Specifically, they had a BRAFV600E/TERTwild-type 1.3 mm thick primary tumor excised from their leg and developed a subsequent regional soft tissue metastasis within one year that lacked a BRAF mutation. Interestingly it possessed NRASQ61K and TERT124C>T mutations, despite not being treated with any BRAF targeted therapy. Subsequently, the patient developed two additional regional soft tissue metastases over 12 years with the same NRAS/TERT mutational profile as the initial regional recurrence (Figure 2a). The mutations detected by SNaPshot were confirmed by Sanger sequencing, and one of the NRAS mutations was identified solely by ddPCR. Interestingly, the patient had no evidence of another melanoma in their medical record, nor was BRAF-targeted therapy administered at any time. The TERTwild-type result could not be confirmed by ddPCR due to insufficient DNA, so this patient was not included in the TERT heterogeneity group.

Figure 2: Representative patients exhibiting inter-tumor heterogeneity.

Figure 2:

(a) Patient 06–001 was diagnosed with a BRAFV600E/NRASwild-type/TERTwild-type** primary tumor (P) and developed a BRAFwild-type/NRASQ61K/TERT−124[C>T] satellite metastasis (M1), 310 days after primary resection. The second metastasis was an in-transit lesion diagnosed 3667 days after initial diagnosis and was BRAFwild-type/NRASQ61K/TERT−124[C>T]. The patient subsequently developed a regional lymphatic metastasis of the same genotype. Sample marked as ** was wild-type by SNaPshot but failed ddPCR analysis (this patient was not included in the TERT heterogeneity group). Scale bars = 800 μm in (P) and (M1), 4 mm in (M2) and 3 mm in (M3).

(b) Patient 06–075 had three metastatic tumors which presented with two unique genotypic profiles, M1: BRAFV600E/NRASQ61K/TERTwild-type, M2: BRAFwild-type/NRASQ61K/TERTwild-type and M3: BRAFwild-type/ NRASQ61K/TERTwild-type. The patient’s primary tumor was located on the trunk, in the mid back region, but tissue was not available for mutational analysis. Scale bars = 2 mm in (M1), 5 mm in (M2) and 4 mm in (M3).

Mutational heterogeneity between patients’ metastatic tumors

To examine inter-tumor heterogeneity between metastatic tumors from individual patients, we analyzed 70 patients with ≥2 available metastases. We found nine patients with different BRAF, NRAS or TERT genotypic profiles between their metastatic tumors (Table 2). Of these nine patients, five displayed additional mutations in metastases that developed at later time points. In seven patients mutations were absent in later metastases. In particular, patient 06–075 had two uniquely different metastatic samples (Figure 2b). Surprisingly, this patient had a BRAFV600E/NRASQ61K metastatic tumor in the left axilla 39 days after diagnosis of their primary melanoma; a BRAFwild-type/NRASQ61K metastatic tumor in the left flank 398 days after diagnosis; and a BRAFwild-type/NRASQ61K metastatic tumor in the left flank 445 days after diagnosis. All three metastases lacked TERT mutations (Table 2).

Intra-tumor heterogeneity in melanomas

Using the ddPCR assays we identified one tumor with both BRAF and NRAS mutations (noted above). The mutant allele frequencies were 0.78% (BRAF) and 1.79% (NRAS) (Figure 2b). In addition, we identified both TERT promoter mutations within seven tumors from seven individual patients (Table 2). Four of the seven samples were primary tumors, the other three were lymphatic metastases. For example patient 04–050 had a primary tumor with TERT−124 [C>T] (allele frequency: 21.9%) and TERT−146 [C>T] (allele frequency: 0.97%), suggesting the presence of both a dominant and minor clone (Figure 3). Overall, the allele frequencies for these mutations ranged from 0.08% to 22.3% and varied in each of the seven tumors, suggesting the presence of different subclones (Table 4). Of note, theses assays do not exhibit any cross-reactivity for the other mutation (Corless et al., 2019).

Figure 3: Representative droplet digital PCR two dimensional plots of TERT promoter mutations from primary tumor DNA (patient 04–050).

Figure 3:

(a) Two dimensional plot of TERT mutation −124[C>T], fractional abundance of 21.9%. (b) Two dimensional plot of TERT mutation −146 [C>T], fractional abundance of 0.97%. Y-axis: mutant allele. X-axis: WT allele. Droplets containing different fragments of DNA are displayed as follows: Single positive mutant allele: upper left quadrant (blue); single positive wild-type allele: lower right quadrant (green); double positive mutant/wild-type alleles: upper right quadrant (orange) and droplets not containing either allele: lower left quadrant (grey).

Table 4: Allele frequencies of TERT promoter mutations in tumors where both mutations were detected using ddPCR.

Allele frequencies for TERT −124[C>T] and TERT −146 [C>T] are listed for each of the seven tumors that displayed a positive result for both assays.

Allele Frequencies (%)
Patient (tumor) TERT -124 [C>T] TERT -146 [C>T]
02–074 (M2) 22.3 0.29
03–103 (M1) 14.5 3.11
04–050 (P2) 21.9 0.97
05–137 (P2) 2.24 0.79
06–002 (M2) 0.08 0.13
07–050 (P) 3.53 2.41
10–018 (P) 4.62 1.67

DISCUSSION

In this study, we investigated the frequency of tumor mutational heterogeneity among genes frequently mutated in melanoma, BRAF, NRAS and TERT. We identified inter-tumor mutational heterogeneity in 18% of nearly 100 patients. This included several cases where a new mutation was found in one or more metastatic tumors, consistent with tumor evolution and the emergence of more highly mutated tumor genotypes over time (Caswell and Swanton, 2017, Maley et al., 2017, Shain et al., 2015). We also had cases in which mutations identified in primary tumors were undetectable in one or more of their metastatic tumors, suggestive of polyclonality in the primary tumor. Among the strengths of this analysis was that we used at least two methods to confirm the mutational status of 91.5% of tumors, and in all 18 patients in which tumor heterogeneity was observed, at least two methods were used to confirm heterogeneity. In particular, we used highly sensitive and specific ddPCR assays (when they became available in the lab – See Supplementary Methods) to assess cases with presumptive inter-tumor mutational heterogeneity initially identified using the less sensitive platforms. We also used UDG treatment of the FFPE tumor-derived DNAs to reduce the possibility of artifactual mutations in the GC-rich TERT promoter. These rigorous analyses resulted in fewer patients with tumor heterogeneity based on TERT mutations than initially identified using SNaPshot analysis alone. We also examined a large number of tumors (n=271) for this type of analysis.

Mutational heterogeneity in melanoma has been explored by many investigators for over 10 years, focusing primarily on BRAF mutations (Colombino et al., 2012, Lin et al., 2011, Sensi et al., 2006). A meta-analysis of all studies with >10 patients concluded that BRAF tumor heterogeneity was found at a rate of 13.4% between the primary and metastatic lesions and 7.3% between metastatic tumors (Valachis and Ullenhag, 2017). Although some authors have questioned these studies, citing either technical issues to explain the lack of detection of mutations in some tumors, or the existence of another primary to explain the presence of mutations in metastatic lesions not detected in the initial primary (Menzies et al., 2014b, Riveiro-Falkenbach et al., 2017, Uguen et al., 2016), our data are in general agreement with the meta-analysis. To address potential technical concerns, we used multiple platforms to confirm mutational heterogeneity, including high sensitivity methods such as ddPCR. To address the concern regarding undiagnosed second-order primary melanomas, we obtained the tumors from our prospective clinical-pathological biorepository that includes complete clinical data and protocol-driven follow up, and included second primary tumors in the few patients in which they occurred. We found BRAF, NRAS and TERT mutational heterogeneity among 7%, 3% and 13% of patients respectively. We are aware of two studies of eight patients each that used whole exome sequencing to assess either for heterogeneity between primary and metastatic lesions (Sanborn et al., 2015) or for intra-tumor heterogeneity (Harbst et al., 2016). Although they did observe a divergence in passenger or late occurring mutations, no heterogeneity in BRAF, NRAS or TERT was found. With only eight patients each, these studies appear underpowered to detect mutational heterogeneity that may occur at rates of 18% or less.

Inter-tumor mutational heterogeneity among patients undergoing targeted therapy is much less controversial, as it has been reported by multiple investigators and is believed to stem from either a polyclonal tumor being subject to selective pressure, or the acquisition of de novo mutations in line with clonal evolution (Maley et al., 2017, Raaijmakers et al., 2016, Shi et al., 2014, Venkatesan et al., 2017, Wilmott et al., 2012). The pre-existence of subclones carrying resistance mutations prior to treatment is directly supported by Kemper at al. who demonstrated that resistance to vemurafenib developed due to the presence of a pre-existing MEK mutation in one of several metastatic tumors analyzed from a single patient (Kemper et al., 2015). In our study, there were two patients who presented with both BRAF and NRAS mutations. One patient developed the NRAS mutation later in their disease course, while the other patient had both mutations in the same metastasis, but only the NRAS mutation persisted among later metastases. NRAS mutations are known to confer resistance to BRAF-targeted therapies; however, neither patient received BRAF targeted therapy at any time during their treatment. Similarly, Sensi et al., in a report prior to the advent of BRAF targeted therapy, detected both BRAFmutant and NRASmutant cells in short term cultures from a single lymph node from a melanoma patient (Sensi et al., 2006). These findings, albeit rare, raise the possibility that the intrinsic nature of melanoma may be the development of multiple subclones throughout tumor evolution, even in the absence of exogenous therapeutic pressure.

Similar to other types of cancer, branched evolution is the current biological model in melanoma (Harbst et al., 2016, McGranahan and Swanton, 2015). In this model, clones stem from a truncal or driver mutation, such as BRAF, and subclones (i.e. branches) are defined by the acquisition of subsequent mutations, such as TERT (Davis et al., 2017, Shain et al., 2015). Additional findings from the current study and published reports support the concept of subclones within melanoma tumors, although they raise questions regarding the truncal nature of BRAF mutations in all cases. For example, several authors, including us, have described many patients in which BRAF mutations appeared to be acquired after the development of metastases, as they were undetected in the paired primary tumor from the same patients. While initially considered to be consistent with a tumor evolution model characterized by the acquisition of mutations, or due to lack of sampling of mutant cells in the primary tumor, this finding alone raises the possibility that BRAF mutations are not necessarily truncal mutations in all cases. A truncal mutation should be present in all cells and rarely missed if tumor cells were sampled from primary tumors of patients in which BRAFmutant metastases arose. In support of the polyclonal hypothesis, Lin et al., performed single cell sequencing on a small number of melanoma primary tumors and detected the presence of both BRAFmutant and BRAFwild-type subclones within the same primary tumor (Lin et al., 2011). Additionally, previous work from our group using laser microdissection identified both BRAFmutant and BRAFwild-type regions within 6/9 primary melanoma tumors (Yancovitz et al., 2012). If primary tumors are comprised of genetically distinct subclones, each capable of metastatic spread, it could explain the absence of a presumed truncal driver mutation among one or more metastatic tumors arising from a primary tumor with a detectable mutation. Alternatively, polyclonality in primary tumors could explain the apparent gain of a truncal driver mutation in a metastatic tumor derived from a primary tumor in which the driver mutation was present in a small, undetectable subclone. Overall we observed these situations in four patients who had BRAF or NRAS driver mutations (Table 3). This observation suggests that in rare cases, truncal driver mutations may only be present in a fraction of the cells in the primary tumor that give rise to metastases.

The current study provides direct evidence to support the presence of melanoma subclones within primary and metastatic tumors. We identified TERT intra-tumoral heterogeneity within four primary and three metastatic tumors. We also identified one metastatic tumor with both BRAF and NRAS mutations. It is generally accepted that TERT promoter mutations, and BRAF and NRAS mutations, exist in a mutually exclusive fashion at the cellular level (Akbani et al., 2015, Sensi et al., 2006). Identifying these mutually exclusive mutations in the same tumor, and at differing allele fractions using validated ddPCR assays (Corless et al., 2019), is consistent with the presence of subclones. Of note, a previous study also identified more than one TERT mutation in the same recurrent melanoma tumor (Walton et al., 2019), and the presence of BRAFmutant and NRASmutant melanoma cells from patient derived short term cultures (Raaijmakers et al., 2016, Sensi et al., 2006).

There are several limitations to this analysis. We restricted our assessment to hot spot mutations within three genes. Whole exome analysis would likely uncover additional heterogeneity and could potentially be associated with patient prognosis, as observed in lung cancer (Jamal-Hanjani et al., 2017). In addition, we were not able to analyze all tumors using ddPCR, our most sensitive method. Taken together, we may be underestimating the rate of heterogeneity. In contrast, we could be overestimating the rate of heterogeneity due to selection bias. Most of the patients with heterogeneity had multiple metastatic tumors. Finally, to more directly support the presence of subclones within the primary tumor, mutational analysis of multiple regions within a tumor (i.e. by laser microdissection) or single-cell analysis would provide further confirmation of the results.

In conclusion, we observed tumor mutational heterogeneity in the three most commonly mutated genes in melanoma. These results suggest that known driver mutations may be subclonal in primary melanomas, albeit in a minority of patients, and that the development of subclones may be inherent to melanoma even in the absence of therapeutic pressure. Our study contributes to the growing evidence of clonal heterogeneity in melanoma. This biological characteristic may be relevant for patient prognosis, could be a source of therapeutic resistance, and thus may be highly relevant for treatment design (McGranahan and Swanton, 2017).

MATERIALS AND METHODS

The detailed protocols are described in Supplemental Materials and Methods online.

Patients and tumors

We studied 271 FFPE tumors from 99 patients with advanced melanoma enrolled in the IRB-approved NYU Interdisciplinary Melanoma Cooperative Group prospective clinical database and biorepository program. All participants provided their written informed consent before enrollment (IRB#10362) (Wich et al., 2009). Only patients with two or more available tumor specimens were included in the study. Tumor content was determined by pathologist’s review of H&E stained slides (n=258) or on the basis of the pathology report when H&E was unavailable (n=13).

Mutational Analysis

Multiplex SNaPshot assays (Applied Biosystems, Foster City, CA) were used to detect BRAFV600E/K, NRASQ61K/L/R, TERT−124 [C>T] (C228T), TERT-146 [C>T] (C250T) mutations. Amplifications were carried out using the GeneAmp PCR System 9700 (Applied Biosystems) with 10ng of genomic DNA according to manufacturer’s instructions.

Quality control multiplatform analysis for BRAF and NRAS hot spot mutations

As a quality control measure for the detection of BRAF and NRAS mutations, 248/271 (91.5%) samples were retested with an orthogonal method (Figure 1a). One hundred seven randomly selected tumor samples were sent to Molecular MD for analysis using Mutation-specific PCR assays (MS-PCR). Two hundred nine samples with sufficient DNA were analyzed via Sanger Sequencing (Genewiz, South Plainfield, NJ). When droplet digital PCR (ddPCR) became available in the lab we tested tumors based on DNA availability to: resolve mutational discordances between other methods (n=2) and explore the sensitivity of the methods with respect to allele fraction as measured by ddPCR (n=28). ddPCR assays were performed according to the manufacturer’s instructions (BioRad Laboratories, Hercules, CA) and as previously described (Syeda et al., 2020).

Quality control multiplatform analysis for TERT promoter mutations

Due to the potential for C>T mutational artifacts to be created by long term formal-infixation (Do and Dobrovic, 2015) all tumor samples from patients initially identified as having tumor heterogeneity based on TERT mutation SNaPshot results were reanalyzed using ddPCR (Corless et al., 2017) following treatment with Uracil DNA Glycosylase (UDG) (n=89 tumors) (Figure 1b). All ddPCR analyses were conducted using a fractional abundance of 0.05% as a threshold for all positive mutation calls (manuscript in preparation).

No datasets were generated or analyzed during the current study.

Supplementary Material

1
2

Acknowledgments

FUNDING SOURCES

Study supported by NIH/NCI Grants: R21 CA154786 (DP), R21 CA198495 (DP), P50 CA225450 (IO), P30 CA016087 (NYU Center for Biospecimen Research and Development); FDA Grant: UO1 FD004203 (DP).

Abbreviations:

ddPCR

droplet digital PCR

WT

wild-type

Footnotes

CONFLICT OF INTEREST STATEMENT

David Polsky was a consultant for Molecular MD until October 2019.

Shria Blake and Cindy Spittle are employees of Molecular MD.

George Karlin-Neumann is an employee of Bio-Rad Laboratories, Inc.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

REFERENCES

  1. Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, et al. Genomic classification of cutaneous melanoma. Cell 2015;161(7):1681–96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Carlino MS, Saunders CA, Haydu LE, Menzies AM, Martin Curtis C Jr., Lebowitz PF, et al. (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. Eur J Cancer 2013;49(2):395–402. [DOI] [PubMed] [Google Scholar]
  3. Caswell DR, Swanton C. The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Med 2017;15(1):133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012;30(20):2522–9. [DOI] [PubMed] [Google Scholar]
  5. Corless B, Chang G, Cooper S, Syeda M, Osman I, Karlin-Neumann G, et al. Detection of TERT C228T and C250T promoter mutations in melanoma tumor and plasma samples using novel mutation-specific droplet digital PCR assays. Cancer Research 2017;77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Corless BC, Chang GA, Cooper S, Syeda MM, Shao Y, Osman I, et al. Development of Novel Mutation-Specific Droplet Digital PCR Assays Detecting TERT Promoter Mutations in Tumor and Plasma Samples. J Mol Diagn 2019;21(2):274–85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Davis A, Gao R, Navin N. Tumor evolution: Linear, branching, neutral or punctuated? Biochimica et Biophysica Acta - Reviews on Cancer 2017;1867(2):151–61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Do H, Dobrovic A. Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization. Clin Chem 2015;61(1):64–71. [DOI] [PubMed] [Google Scholar]
  9. Harbst K, Lauss M, Cirenajwis H, Isaksson K, Rosengren F, Törngren T, et al. Multiregion whole-exome sequencing uncovers the genetic evolution and mutational heterogeneity of early-stage metastatic melanoma. Cancer research 2016;76(16):4765–74. [DOI] [PubMed] [Google Scholar]
  10. Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TB, Veeriah S, et al. Tracking the evolution of non–small-cell lung cancer. New England Journal of Medicine 2017;376(22):210921. [DOI] [PubMed] [Google Scholar]
  11. Kemper K, Krijgsman O, Cornelissen-Steijger P, Shahrabi A, Weeber F, Song JY, et al. Intra- and intertumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. EMBO Mol Med 2015;7(9):1104–18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lin J, Goto Y, Murata H, Sakaizawa K, Uchiyama A, Saida T, et al. Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. British journal of cancer 2011;104(3):464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, et al. Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer 2017;17(10):605–19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer cell 2015;27(1):15–26. [DOI] [PubMed] [Google Scholar]
  15. McGranahan N, Swanton C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell 2017;168(4):613–28. [DOI] [PubMed] [Google Scholar]
  16. Menzies AM, Haydu LE, Carlino MS, Azer MW, Carr PJ, Kefford RF, et al. Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma. PLoS One 2014a;9(1):e85004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Menzies AM, Wilmott JS, Long GV, Scolyer RA. Intra-patient heterogeneity of BRAF mutation status: fact or fiction? Br J Cancer 2014b;111(8):1678–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Raaijmakers MI, Widmer DS, Narechania A, Eichhoff O, Freiberger SN, Wenzina J, et al. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance. Oncotarget 2016;7(47):77163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Riveiro-Falkenbach E, Santos-Briz A, Rios-Martin JJ, Rodriguez-Peralto JL. Controversies in Intrapatient Melanoma BRAFV600E Mutation Status. Am J Dermatopathol 2017;39(4):291–5. [DOI] [PubMed] [Google Scholar]
  20. Sanborn JZ, Chung J, Purdom E, Wang NJ, Kakavand H, Wilmott JS, et al. Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proc Natl Acad Sci U S A 2015;112(35):10995–1000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A, et al. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 2006;25(24):3357–64. [DOI] [PubMed] [Google Scholar]
  22. Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med 2015;373(20):1926–36. [DOI] [PubMed] [Google Scholar]
  23. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer discovery 2014;4(1):80–93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Syeda MM, Wiggins JM, Corless B, Spittle C, Karlin-Neumann G, Polsky D. Validation of Circulating Tumor DNA Assays for Detection of Metastatic Melanoma. Methods Mol Biol 2020;2055:155–80. [DOI] [PubMed] [Google Scholar]
  25. Uguen A, Talagas M, Marcorelles P, De Braekeleer M. BRAFV600E and NRASQ61R Homogeneity in Melanoma Tumors. J Invest Dermatol 2016;136(1):337–8. [DOI] [PubMed] [Google Scholar]
  26. Valachis A, Ullenhag GJ. Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis. Eur J Cancer 2017;81:106–15. [DOI] [PubMed] [Google Scholar]
  27. Venkatesan S, Swanton C, Taylor BS, Costello JF. Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution. Cold Spring Harb Perspect Med 2017;7(8). [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Walton KE, Garfield EM, Zhang B, Quan VL, Shi K, Mohan LS, et al. The role of TERT promoter mutations in differentiating recurrent nevi from recurrent melanomas: A retrospective, case-control study. J Am Acad Dermatol 2019;80(3):685–93. [DOI] [PubMed] [Google Scholar]
  29. Wich LG, Hamilton HK, Shapiro RL, Pavlick A, Berman RS, Polsky D, et al. Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. Am J Transl Res 2009;1(1):35–43. [PMC free article] [PubMed] [Google Scholar]
  30. Wilmott JS, Tembe V, Howle JR, Sharma R, Thompson JF, Rizos H, et al. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. Mol Cancer Ther 2012;11(12):2704–8. [DOI] [PubMed] [Google Scholar]
  31. Yancovitz M, Litterman A, Yoon J, Ng E, Shapiro RL, Berman RS, et al. Intra-and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One 2012;7(1):e2933 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1
2

RESOURCES